Ascelia Pharma Q1: FDA submission on track for mid-year, most likely early August - Redeye

The FDA submission is progressing toward the finish line, as illustrated by the more precise expected time of submission by the first half of August. Orviglance continues to get attention at conferences like ESGAR (May) and ISPOR (May), creating opportunities to interact with already engaged and additional potential partners ahead of the US Orviglance launch in 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109444/ascelia-pharma-q1-fda-submission-on-track-for-mid-year-most-likely-early-august?utm_source=finwire&utm_medium=RSS